The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

被引:7
|
作者
Jamous, Yahya F. [1 ]
Alhomoud, Dalal A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol, Natl Ctr Vaccine & Bioproc, Riyadh, Saudi Arabia
关键词
safety; efficacy; vaccines; mrna; sars-cov-2; COVID-19; VACCINE; HYPERSENSITIVITY; OUTCOMES; SEX;
D O I
10.7759/cureus.45602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and PfizerBioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
    Echaide, Miriam
    de Erauso, Luisa Chocarro
    Bocanegra, Ana
    Blanco, Ester
    Kochan, Grazyna
    Escors, David
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [2] Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms
    Gohda, Eiichi
    JOURNAL OF DISASTER RESEARCH, 2022, 17 (01) : 7 - 20
  • [3] Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
    Li, Jianglong
    Liu, Qi
    Liu, Jun
    Fang, Zihui
    Luo, Liping
    Li, Shuang
    Lei, Yixin
    Li, Zhi
    Jin, Jing
    Xie, Ronglin
    Peng, Yucai
    VACCINES, 2022, 10 (11)
  • [4] Booster vaccination with mRNA vaccines against SARS-CoV-2 virus
    Pecks, Ulrich
    Schleussner, Ekkehard
    Zollkau, Janine
    Scharl, Anton
    Kehl, Sven
    Hagenbeck, Carsten
    Schlembach, Dietmar
    Abou-Dakn, Michael
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02) : 130 - 130
  • [5] Safety of Sars-cov-2 Mrna Vaccines in Solid Organ Transplant Recipients
    Ou, M.
    Boyarsky, B.
    Motter, J.
    Greenberg, R.
    Teles, A.
    Ruddy, J.
    Krach, M.
    Werbel, W.
    Avery, R.
    Massie, A.
    Segev, D.
    Garonzik-Wang, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 418 - 418
  • [6] Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients
    Hirama, Takashi
    Akiba, Miki
    Shundo, Yuki
    Watanabe, Tatsuaki
    Watanabe, Yui
    Oishi, Hisashi
    Niikawa, Hiromichi
    Okada, Yoshinori
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (08) : 1153 - 1158
  • [7] DELAYED SKIN REACTIONS AND MRNA VACCINES AGAINST SARS-COV-2: CORRESPONDENCE
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    EXCLI JOURNAL, 2022, 21 : 1285 - 1285
  • [8] Maintaining Safety with SARS-CoV-2 Vaccines
    Rolla, Giovanni
    Brussino, Luisa
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10):
  • [9] Maintaining Safety with SARS-CoV-2 Vaccines
    Castells, Mariana C.
    Phillips, Elizabeth J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 643 - 649
  • [10] Development of vaccines against SARS-CoV-2
    Leon-Lara, Ximena
    Otero-Mendoza, Francisco
    ACTA PEDIATRICA DE MEXICO, 2020, 41 (04): : S23 - S26